Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Ann Med Surg (Lond) ; 86(4): 1867-1872, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38576952

RESUMEN

Background: Conventional peroral methods to visualize biliary strictures are not feasible in some patients with altered anatomy or biliary obstruction, and percutaneous transhepatic cholangioscopy can be used as an alternative procedure. This study aimed to retrospectively review the use of percutaneous transhepatic cholangiography using the SpyGlass DS technology (S-PTCS) during a 5-year period at a Danish tertiary referral centre. Materials and methods: All patients who underwent S-PTCS at a single Danish tertiary referral centre between 2016 and 2021 were retrospectively analyzed. The visual, technical, and overall success rates of S-PTCS were analyzed, as well as the complication rate. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of S-PTCS were calculated. Results: Twenty-two patients were included in the study. Visual, technical, and overall success of S-PTCS was achieved in 17/22, 22/22, and 21/22 patients, respectively. S-PTCS yielded a sensitivity of 83.3%, a specificity of 100%, a PPV of 100%, a NPV of 94.1%, and an accuracy of 95.4%. Complications occurred in 1/22 patients. Conclusion: S-PTCS is a safe modality, with high success rates, high predictive values, and a low rate of complications. This study suggests that S-PTCS is an alternative to conventional methods in patients with indeterminate biliary strictures where conventional methods were unfeasible.

2.
Scand J Surg ; 112(2): 86-90, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36756673

RESUMEN

BACKGROUND AND OBJECTIVE: Barrett's esophagus (BE) is associated with an increased risk of esophageal adenocarcinoma. The use of radio frequency ablation (RFA) for complete eradication of BE with confirmed low-grade dysplasia (LGD) or high-grade dysplasia (HGD) has been promising in multicenter trials. Our aim was to evaluate the safety and efficacy outcomes associated with RFA for patients with BE and LGD/HGD in a single-center setting. METHODS: This was a retrospective single-center study conducted at Department of Surgery and Transplantation, Rigshospitalet, Denmark. Data were collected from all patients who had undergone RFA for LGD or HGD from January 2014 to December 2018. Effectiveness outcomes were based on histology: complete eradication of dysplasia (CE-D), defined as all esophageal biopsies being negative for dysplasia at the last biopsy session, and complete eradication of intestinal metaplasia (CE-IM) defined as esophageal biopsies being without intestinal metaplasia. Safety outcomes were based on the proportion of complications to the RFA treatment. RESULTS: A total of 107 patients were identified during the follow-up period (75% men, median age = 65 years); 83% had LGD and 17% had HGD. The median follow-up was 25 months. After the last RFA treatment, CE-D was achieved in 89%. CE-D and CE-IM were achieved in 60%. Complications occurred in 6.5% of the patients. CONCLUSIONS: In patients with BE and confirmed LGD or HGD, RFA was associated with a high rate of CE-D and a low risk of complications. The observed safety and efficacy outcomes were comparable with those previously reported in multicenter trials, showing that the Danish treatment of BE with LGD and HGD is comparable with those of larger European expert centers.


Asunto(s)
Esófago de Barrett , Ablación por Catéter , Neoplasias Esofágicas , Lesiones Precancerosas , Ablación por Radiofrecuencia , Masculino , Humanos , Anciano , Femenino , Esófago de Barrett/cirugía , Esófago de Barrett/patología , Estudios Retrospectivos , Resultado del Tratamiento , Neoplasias Esofágicas/cirugía , Neoplasias Esofágicas/patología , Metaplasia , Hiperplasia , Sistema de Registros , Esofagoscopía , Lesiones Precancerosas/patología
3.
Langenbecks Arch Surg ; 407(8): 3407-3412, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36205840

RESUMEN

PURPOSE: The aim of this study was to examine whether collagenase producing bacteria could be detected, in fluid collected from chest tubes, before clinical presentation of anastomotic leakage after esophageal resection. METHODS: We conducted a prospective single-center study of patients who underwent resection of the gastroesophageal junction. All patients had a chest tube placed in the pleural cavity perioperatively. Drain fluid was collected and cultured from the first post-operative day and at time of routine removal of the drain (days 3-5). RESULTS: From January 2018 to July 2019, a total of 84 patients were included in the study. Twenty (36%) patients experienced severe complications with a Clavien-Dindo score of 3b-5. Eleven (13%) patients were diagnosed with anastomotic leakage which occurred after 8 days (mean, range 2-13). Twenty patients (24%) had drain samples with significant growth of microbes. Among the 11 patients with anastomotic leakage, we found 2 with microbe growth at POD 2 and POD 4, the remaining 9 samples were negative (p = 0.638). Thirty-day mortality rate was zero. CONCLUSION: Cultured fluid from the pleural cavity of asymptomatic patients following esophageal resection did not indicate a significant association with anastomotic leakage.


Asunto(s)
Fuga Anastomótica , Neoplasias Esofágicas , Humanos , Fuga Anastomótica/diagnóstico , Tubos Torácicos/efectos adversos , Estudios Prospectivos , Esófago/cirugía , Esofagectomía/efectos adversos , Anastomosis Quirúrgica/efectos adversos , Neoplasias Esofágicas/cirugía , Estudios Retrospectivos
4.
World J Gastrointest Endosc ; 12(10): 388-400, 2020 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-33133375

RESUMEN

BACKGROUND: Conventional endoscopy is based on full spectrum white light. However, different studies have investigated the use of fluorescence based endoscopy systems where the white light has been supplemented by infrared light and the use of relevant fluorophores. Fluorescence endoscopy utilizes the fluorescence emitted from a fluorophore, visualizing what is not visible to the naked eye. AIM: To explore the feasibility of fluorescence endoscopy and evaluate its use in diagnosing and evaluating gastrointestinal disease. METHODS: We followed the PRISMA guidelines for this systematic review. The research covered five databases; PubMed, Scopus, Web of Science, Embase, and the Cochrane Collection, including only studies in English and Scandinavian languages. Authors screened title and abstract for inclusion, subsequently full-text for inclusion according to eligibility criteria listed in the protocol. The risk of bias was assessed for all studies according to the Newcastle-Ottawa Scale. The authors extracted the data and reported the results in both text and tables. RESULTS: We included seven studies in the systematic review after screening a total of 2769 papers. The most prominent fluorophore was indocyanine green (n = 6), and whereas one study (n = 1) used Bevacizumab 800-CW. Three studies investigated fluorescence endoscopy in detecting varices, adenomas in patients with familial adenomatous polyposis and neoplasms in the gastrointestinal tract. Four studies evaluated the usefulness of fluorescence endoscopy in assessing tumor invasion. Three of the four studies reported an exceptional diagnostic accuracy (93%, 89% and 88%) in assessing tumor invasion, thus representing better visualization and more correct diagnosis by fluorescence endoscopy compared with the conventional endoscopy. The relationship between the endoscopic findings, tumor invasion, and tumor vascularity was evaluated in two studies showing a significant correlation (d P < 0.05 and b P < 0.01). CONCLUSION: The use of fluorescence endoscopy is a promising method adding diagnostic value in the detection of neoplasia, adenomas, and assessment of tumor invasion within the gastrointestinal tract. More studies are needed to utilize the feasibility of fluorescence endoscopy compared with other endoscopic methods.

6.
World J Surg ; 41(6): 1575-1583, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28078353

RESUMEN

BACKGROUND: The literature on oral intake after esophagectomy and its influence on anastomotic leakage and complications is sparse. METHODS: This retrospective study included 359 patients undergoing esophagectomy between January 2011 and August 2015. Three oral intake protocols were evaluated: regimen 1, nil by mouth until postoperative day (POD) 7 followed by a normal diet; regimen 2, oral intake of clear fluids from POD 1 followed by a normal diet; regimen 3, nil by mouth until POD 7 followed by a slow increase to a blended diet. The outcome endpoints were: (1) anastomotic leakage, (2) complications [severity and number described using the Dindo-Clavien Classification and Comprehensive Complication Index (CCI)] and (3) length of stay. A multivariate logistic regression model was obtained for CCI and anastomotic leakage using Wald's stepwise selection. RESULTS: CCI was significantly lower in regimen 3 (16 vs. 22 and 26 in regimen 1 and 2, p = 0.027). Additionally, significantly fewer patients in regimen 3 suffered from severe complications of Dindo-Clavien grade IIIb-IV (p = 0.025). The incidence of anastomotic leakage reached its lowest in regimen 3, 2%, compared to 7-9%. Multivariate analyses revealed that high American Society of Anesthesiologist score was a predicting factor for both CCI and anastomotic leakage. CONCLUSION: The study indicates that nil by mouth until postoperative day 7 followed by a slow increase to a blended diet after esophagectomy results in less severe complications and a tendency of fewer anastomotic leakages. Multiple comorbidities proved to be an important predictive factor of the postoperative course.


Asunto(s)
Dieta , Esofagectomía/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Fuga Anastomótica/epidemiología , Fuga Anastomótica/etiología , Femenino , Humanos , Tiempo de Internación , Modelos Logísticos , Masculino , Persona de Mediana Edad , Boca , Estudios Retrospectivos
8.
Ugeskr Laeger ; 176(32): 1490-3, 2014 Aug 04.
Artículo en Danés | MEDLINE | ID: mdl-25292471

RESUMEN

Despite chemotherapy and intended curative surgery, approximately 50% of patients with gastric cancer develop recurrence and eventually die of metastatic disease. The detection of circulating tumour cells (CTC) in peripheral blood is a promising prognostic and predictive marker. The most typically applied approaches to the detection of CTC are RT-PCR and immunological assays. Measurement of CTC in gastric cancer seems useful for predicting prognosis and monitoring response of chemotherapy. There is still no gold standard for CTC-detection in gastric cancer patients and larger studies are needed.


Asunto(s)
Biomarcadores de Tumor/análisis , Células Neoplásicas Circulantes/patología , Neoplasias Gástricas/diagnóstico , Antígenos de Neoplasias/análisis , Separación Celular , Citometría de Flujo , Humanos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Neoplasias Gástricas/sangre , Neoplasias Gástricas/patología
9.
Int J Colorectal Dis ; 27(12): 1579-86, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22710688

RESUMEN

PURPOSE: A 128-gene signature has been proposed to predict outcome in patients with stages II and III colorectal cancers. In the present study, we aimed to reproduce and validate the 128-gene signature in external and independent material. METHODS: Gene expression data from the original material were retrieved from the Gene Expression Omnibus (GEO) (n = 111) in addition to a Danish data set (n = 37). All patients had stages II and III colon cancers. A Prediction Analysis of Microarray classifier, based on the 128-gene signature and the original training set of stage I (n = 65) and stage IV (n = 76) colon cancers, was reproduced. The stages II and III colon cancers were subsequently classified as either stage I-like (good prognosis) or stage IV-like (poor prognosis) and assessed by the 36 months cumulative incidence of relapse. RESULTS: In the GEO data set, results were reproducible in stage III, as patients predicted to be stage I-like had a significant lower risk of relapse than patients predicted as stage IV-like (P = 0.04, Gray test). Results were not reproducible in stage II patients (P > 0.05, Gray test). In the Danish data set, two of four stage III patients with relapse were correctly predicted as stage IV-like, and the remaining patients were predicted as stage I-like and unclassifiable, respectively. Stage II patients could not be stratified. CONCLUSIONS: The 128-gene signature showed reproducibility in stage III colon cancer, but could not predict recurrence in stage II. Individual patient predictions in an independent Danish material were unsatisfactory. Additional validation in larger cohorts is warranted.


Asunto(s)
Neoplasias del Colon/genética , Neoplasias del Colon/patología , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Anciano , Anciano de 80 o más Años , Neoplasias del Colon/epidemiología , Bases de Datos Genéticas , Dinamarca/epidemiología , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Reproducibilidad de los Resultados
10.
Anticancer Res ; 31(2): 613-7, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21378346

RESUMEN

BACKGROUND: The aim of the present study was to detect circulating tumor cells (CTCs) in the peripheral blood of patients with non-metastatic colon cancer and to evaluate whether there is a diurnal variation in the CTC counts. Furthermore, the study aimed to examine the correlation between CTCs and TNM stage, other paraclinical variables and prognosis. PATIENTS AND METHODS: Blood samples were collected from 20 consecutive patients with colon cancer TNM stage I-III at four different perioperative time points. Detection of CTCs was performed using the immunological assay CellSearch®. RESULTS: CTCs were detected in 1 out of 60 preoperative blood samples, resulting in a detection rate of 1 in 20 patients (5%; 95% confidence interval = 0.1-25%). None of the postoperative blood samples had CTC levels above the cut-off value (≥ 2 CTCs/7.5 ml blood). CONCLUSION: The presence of CTCs in non-metastatic colon cancer is rare and barely detectable with the only commercially available assay for detection of CTCs, the CellSearch System.


Asunto(s)
Adenocarcinoma/sangre , Neoplasias del Colon/sangre , Células Neoplásicas Circulantes/patología , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Ritmo Circadiano , Neoplasias del Colon/patología , Neoplasias del Colon/cirugía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/sangre , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA